VKTX stock attracts retail investors’ interest before Q4 earnings announcement on Stocktwits.

VKTX shares have caught the attention of retail investors as the company gears up to release its fourth-quarter earnings report. Stocktwits data indicates that the volume of messages related to VKTX stock has more than tripled in the past 24 hours, reflecting growing interest in the company.

With expectations for a loss of $0.91 per share in the fourth quarter of 2025, compared to a loss of $0.32 in the same period the previous year, Viking Therapeutics, a clinical-stage biotech firm without any products on the market, is preparing to disclose its financial performance shortly.

One notable aspect of Viking Therapeutics’ pipeline is VK2735, its lead candidate for weight loss, currently in late-stage trials. The subcutaneous formulation of this drug has shown promising results, with patients achieving up to a 14.7% mean weight loss in just 13 weeks during a mid-stage trial. The company is also exploring a tablet formulation of this drug, pointing to potential future growth opportunities.

The CEO of Viking Therapeutics, Brian Lian, highlighted the strategic interest in the weight loss drug market during a recent conference, emphasizing that there is more interest in the space than might initially meet the eye. Lian expressed openness to outside interest in the obesity program, suggesting that partnering with a larger player could accelerate the path to commercialization although remaining open to pursuing the initiative independently if necessary.

Retail investors on Stocktwits are demonstrating a renewed bullish sentiment towards VKTX stock, noting the potential for acquisition and the company’s competitive positioning with weight loss drugs. Despite recent price fluctuations, there is optimism about the future trajectory of Viking Therapeutics, especially as the market eagerly awaits the fourth-quarter earnings report.

While VKTX stock has experienced a 7% decline in the last year, the upcoming financial results and ongoing development of the company’s weight loss drug pipeline could change the narrative surrounding Viking Therapeutics in the biotech industry. Investors are closely monitoring these developments, anticipating how they may impact the company’s performance and market positioning moving forward.